CMC Biologics, a provider of process development and contract manufacturing services, and Zymeworks Inc., a Canadian biotherapeutics company, have entered into a master services agreement for process development, formulation development, and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric) antibody.

Zymeworks is a privately held biotherapeutics company that is developing bi‑specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity, and inflammatory diseases. The pact helps to move Zymeworks’ oncology program into clinical trials for the treatment of breast cancer and other solid tumors, as well as subsequent therapeutic candidates targeted towards hematological cancers such as leukemia and lymphoma.

Source: CMC Biologics